Cinnamon (Ceylon and cassia)
A real fasting glucose signal that fades at the measure that matters, split between the studied form and the safe one.
C+
Evidence grade
C+
Worth it
$8-12/month
Typical cost
DoseThe trial doses are cassia at 1 to 6 g/day (Khan 2003), most later trials at 1 to 3 g/day of powder or extract, over 40 days to four months. The 2025 review's HbA1c signal sat in the subgroup at 2 g/day or less. Ceylon products are sold at similar gram doses on a much thinner trial base, and the coumarin arithmetic in the safety notes is why the form matters at these intakes.
BasisThe blood sugar claim has a real trial base and a consistent shape across two decades: a small fasting glucose effect that fades when the outcome is HbA1c, the three-month measure clinicians actually judge control by.
Cinnamon is sold in two forms that this record grades together, because a reader choosing between them needs both halves at once. We grade Cinnamon (Ceylon and cassia) C+ on evidence and C+ for worth-it at about $8-12 per month.
Questions
Answers come straight from this record's graded evidence.
Does cinnamon lower blood sugar?
If you take glucose-lowering medication, treat cinnamon as an interaction decision first, because its effect adds to medication by design; that caution leads because the blood sugar effect is the point and the risk together. On the evidence: pooled trials find fasting glucose down about 25 mg/dL (Allen et al. 2013, 10 randomized trials, 543 people), and a 2025 pooling of 28 trials found the fasting effect again. The harder measure does not follow consistently: HbA1c showed no significant change in Allen, Cochrane judged the glycemic effect inconclusive in 2012, and an HbA1c reduction appears only in the 2025 subgroup at 2 g a day or less. Our record grades cinnamon C+ on evidence and C+ for worth-it at $8 to $12 a month.
nearly all the trial evidence is cassia, the form carrying the coumarin load; Ceylon has the thinner base, and the large effects of the 2003 origin trial (Khan et al.) have never been reproduced at size.
How much cinnamon is too much?
For cassia, the ceiling is set by coumarin, not by the spice itself: cassia carries roughly 5.8 to 12.1 mg of coumarin per teaspoon against a trace in Ceylon, and the EFSA tolerable daily intake for coumarin is 0.1 mg per kg of body weight, so a daily gram-level cassia habit can pass the ceiling on its own, before any supplement is counted. Case reports of liver injury sit at heavy intakes. Anyone on glucose-lowering medication has a second ceiling: cinnamon lowers glucose in its own right, additively with medication.
Ceylon avoids the coumarin problem and has the thinner evidence base; the record states that trade rather than presenting the switch as free, and culinary use of either form is not the exposure this answer grades.
How much cinnamon should I take?
If you take glucose-lowering medication, that conversation comes first: the trials' effect is additive with medication by design. The studied range is 1 to 6 g a day of cassia (Khan 2003), most commonly 1 to 3 g a day of powder or extract equivalents, for 40 days to four months; the one HbA1c subgroup signal sat at 2 g a day or less, so the top of the range buys coumarin load, not extra effect. Ceylon's own trial doses are fewer and smaller. Our record grades cinnamon C+ on evidence and C+ for worth-it at $8 to $12 a month.
a dose answer for cinnamon is inseparable from the form answer; the same grams are a different exposure in cassia and Ceylon.
What it does
Cinnamon is sold in two forms that this record grades together, because a reader choosing between them needs both halves at once. Cassia, the common and cheaper form, is what nearly every blood sugar trial tested. Ceylon, sold as true cinnamon at a premium, carries a trace of cassia's coumarin but only a thin trial base of its own. The compounds behind the glucose effect are the bark's polyphenols; the compound behind the safety limit is coumarin, and the two forms trade places on which one they supply.
What the research says
Lowers fasting blood glucose in type 2 diabetes
Evidence: C+. Pooled reduction of roughly 25 mg/dL across 10 trials (Allen 2013), nearly all of it cassia; the effect is real at the surrogate and modest.
Lowers HbA1c
Evidence: C. Inconsistent across the literature: null in Allen 2013 and inconclusive at Cochrane; a reduction appears in a 2025 subgroup at 2 g a day or less, which is a subgroup finding, not the headline.
Prevents progression from prediabetes
Evidence: D+. One small trial (500 mg three times daily, 12 weeks) found fasting glucose held steady on cinnamon while rising on placebo: a hint, not a result.
The blood sugar claim has a real trial base and a consistent shape across two decades: a small fasting glucose effect that fades when the outcome is HbA1c, the three-month measure clinicians actually judge control by. The origin trial (Khan 2003) reported fasting drops up to nearly a third at 1 to 6 g/day of cassia; no later pooling has reproduced anything near that size. Allen et al. (2013, 10 trials, 543 people) found fasting glucose down about 25 mg/dL with no significant HbA1c change, Cochrane (2012) judged the effect inconclusive overall, and a 2025 review of 28 trials found the fasting effect again with HbA1c moving only at 2 g/day or less. Replicated surrogate signal, inconsistent hard measure, small short trials, species and formulation varying across the base: that is the C+ shape in this library, one band above chromium and gymnema (C-), whose bases are thinner, and one below berberine (B-), whose HbA1c effects replicate more consistently.
Is it worth it?
Evidence (C+) sits below the evidence bar for the ranking, which caps the worth-it grade at C+ however it is priced; the derived value at about $10 a month lands at C+. The cheap form is the studied one, which is also the one with the coumarin ceiling, so the grade buys the fasting signal only inside the safety arithmetic on this page.
Typical cost
$8-12/month
Common form, not a brand recommendation
Dosage context verified
The trial doses are cassia at 1 to 6 g/day (Khan 2003), most later trials at 1 to 3 g/day of powder or extract, over 40 days to four months. The 2025 review's HbA1c signal sat in the subgroup at 2 g/day or less. Ceylon products are sold at similar gram doses on a much thinner trial base, and the coumarin arithmetic in the safety notes is why the form matters at these intakes.
The worth-it ranking
Cinnamon (Ceylon and cassia) sits outside the worth-it ranking of 38.
Cinnamon (Ceylon and cassia) sits outside that ranking of 38. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Anyone taking glucose-lowering medication should treat cinnamon as additive: the fasting glucose effect is the point of the supplement and the source of the interaction. The safety centre is the form split. Nearly all the trial data sit in cassia, and cassia carries the coumarin load, roughly 5.8 to 12.1 mg per teaspoon against a trace in Ceylon, with the EFSA tolerable daily intake at 0.1 mg/kg of body weight, so the better-studied form is the one a daily gram-level habit can push past the coumarin ceiling; case reports of liver injury exist at heavy intakes. Ceylon is the low-coumarin form sold at a premium, and its own blood sugar trial base is thin: switching forms on safety grounds trades evidence away, and this record says so rather than presenting Ceylon as the same benefit with no cost. Talk to your doctor. This page is information, not medical advice.
Related articles
- Super Veggie and Nutty Pudding, Recosted: The Lunch Is 510 Calories, Not the Circulating 379, and the Brazil Nut Contradicts His Own Archive
The recipes are his. The arithmetic is ours, from the USDA database, and it disagrees with the number the internet repeats for the lunch by about a third.
Emily Hart · November 17, 2026
- Cinnamon for Blood Sugar: The Form With the Trials Is the Form With the Limit
The evidence and the safety sit on opposite forms of the same spice, and the grade has to hold both at once.
Daniel Cole · November 17, 2026
Changelog
Last updated 2026-11-11
- 2026-11-11|Initial grading: Research's weekly deep dive of 2026-11-02 (cinnamon section), integrated on its ruled slot (Nov 11, the top undated candidate behind the dated set). One record carries the form split inside it per the dive's form ruling (the vitamin K2 treatment): cassia holds nearly all the trial data and the coumarin load; Ceylon is the low-coumarin form with the thin trial base.
The week's longevity and biohacking news.
Every story graded against the evidence. Free. Unsubscribe anytime.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric. Sponsors do not influence findings or grades.